Search / Trial NCT00000695

Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of December 10, 2023

Completed

Keywords

Drug Evaluation Drug Therapy, Combination Acquired Immunodeficiency Syndrome Zidovudine Interferon Type I

Description

IFN-B has demonstrated a dose-dependent ability to suppress the replication of HIV in the test tube. In addition, previous studies have shown AZT to be an effective inhibitor of HIV reverse transcriptase; Phase I and II study benefits of AZT treatment include increased objective clinical improvement, decreased mortality rate, and decreased incidence of opportunistic infections. Long-term AZT use, however, presents possible limitations secondary to intolerance. This study, therefore, will investigate the potential antiviral activities of a combination of IFN-B and AZT to determine the safety...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Treatment:
  • Allowed:
  • Local radiotherapy or laser therapy to cosmetically apparent Kaposi's lesions, provided the dose to any one lesion does not exceed 3000 gray and the total surface area of all lesions treated does not exceed 10 cm2 during the course of the trial.
  • Patients must demonstrate the following clinical and laboratory findings:
  • Positive for HIV by federally licensed ELISA test.
  • Acceptable bone marrow function.
  • Acceptable renal function.
  • Acceptable hepatic function.
  • Exclusion Criteria
  • Concurrent Medication:
  • Excluded:
  • Other potentially antiretroviral compounds.
  • Patients will be excluded from the study for the following reasons:
  • Concurrent, active opportunistic infections requiring therapy.
  • Extensive Kaposi's sarcoma with more than 100 cutaneous lesions, requiring systemic chemotherapy, prior treatment with more than one chemotherapy regimen, excluding intralesional therapy, or symptomatic visceral Kaposi's sarcoma.
  • Evidence of clinically significant cardiac dysfunction (New York Heart Association grade III or IV).
  • History of malignant neoplasms other than nonmelanomatous skin cancer or cancer in situ of the cervix.
  • Proteinuria of 2+ or greater and/or 24-hour urine protein of greater than 1.
  • Prior Medication:
  • Excluded:
  • More than one chemotherapy regimen for Kaposi's sarcoma.
  • Any interferon preparation or zidovudine (AZT).
  • Excluded within 30 days of study entry:
  • Other immunomodifiers.
  • Acyclovir.
  • Other investigational drugs.
  • Excluded within 60 days of study entry:
  • Cytotoxic therapy.
  • Patients may not have any of the following diseases or symptoms:
  • Development of an AIDS-defining opportunistic infection, other than oral thrush or localized zoster.
  • Non-Kaposi's sarcoma, AIDS-defining malignancy.

Attachments

readout_NCT00000695_2023-12-10.pdf

4.5 MB

NCT00000695_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Los Angeles, California, United States

Chicago, Illinois, United States

Los Angeles, California, United States

Los Angeles, California, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0